Comparative functional analysis of dpyd variants of potential clinical relevance to dihydropyrimidine dehydrogenase activity

Cancer Research

Volumn 74, Issue 9, 2014, Pages 2545-2554

  Offer, Steven M ^a   Fossum, Croix C ^a   Wegner, Natalie J ^a   Stuflesser, Alexander J ^a,c   Butterfield, Gabriel L ^a   Diasio, Robert B ^a,b  

^a MAYO GRADUATE SCHOOL   (United States)

^b MAYO CLINIC CANCER CENTER   (United States)

^c PARACELSUS MEDICAL UNIVERSITY   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

DIHYDROFLUOROURACIL; DIHYDROPYRIMIDINE DEHYDROGENASE; FLUOROURACIL;

ARTICLE; CONTROLLED STUDY; DPYD GENE; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME DEGRADATION; GENE EXPRESSION; GENE FREQUENCY; GENE FUNCTION; GENE IDENTIFICATION; GENETIC VARIABILITY; GENOTYPE; HUMAN; HUMAN CELL; PRIORITY JOURNAL; WILD TYPE;

AMINO ACID SEQUENCE; ANTIMETABOLITES, ANTINEOPLASTIC; BIOTRANSFORMATION; DIHYDROURACIL DEHYDROGENASE (NADP); ENZYME ASSAYS; FLUOROURACIL; GENE FREQUENCY; GENETIC ASSOCIATION STUDIES; HEK293 CELLS; HUMANS; MOLECULAR SEQUENCE DATA; MUTATION, MISSENSE;

EID: 84900017007     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-13-2482     Document Type: Article

References (38)

1. Meinsma R, Fernandez-Salguero P, Van Kuilenburg AB, Van Gennip AH, Gonzalez FJ. Human polymorphism in drug metabolism: mutation in the dihydropyrimidine dehydrogenase gene results in exon skipping and thymine uracilurea. DNA Cell Biol 1995;14:1-6
2. van Kuilenburg AB, Hausler P, Schalhorn A, Tanck MW, Proost JH, Terborg C, et al. Evaluation of 5-fluorouracil pharmacokinetics in cancer patients with a c.1905+1G>A mutation in DPYD by means of a Bayesian limited sampling strategy. Clin Pharmacokinet 2012;51: 163-74
3. Johnson MR, Hageboutros A, Wang K, High L, Smith JB, Diasio RB. Life-threatening toxicity in a dihydropyrimidine dehydrogenase-deficient patient after treatment with topical 5-fluorouracil. Clin Cancer Res 1999;5:2006-11
4. Schwab M, Zanger UM, Marx C, Schaeffeler E, Klein K, Dippon J, et al. Role of genetic and nongenetic factors for fluorouracil treatment- related severe toxicity: a prospective clinical trial by the German 5-FU Toxicity Study Group. J Clin Oncol 2008;26:2131-8
5. Offer SM, Lee AM, Mattison LK, Fossum C, Wegner NJ, Diasio RB. A DPYD variant (Y186C) in individuals of African Ancestry is associated with reduced DPD enzyme activity. Clin Pharmacol Ther 2013;94: 158-66
6. Johnson MR, Wang K, Diasio RB. Profound dihydropyrimidine dehydrogenase deficiency resulting from a novel compound heterozygote genotype. Clin Cancer Res 2002;8:768-74
7. Morel A, Boisdron-Celle M, Fey L, Soulie P, Craipeau MC, Traore S, et al. Clinical relevance of different dihydropyrimidine dehydrogenase gene single nucleotide polymorphisms on 5-fluorouracil tolerance. Mol Cancer Ther 2006;5:2895-904
8. Exome Variant Server. Seattle (WA): NHLBI GO Exome Sequencing Project (ESP). (EVS data release ESP6500SI-V2). [cited 2013 Apr 25]; Available from: http://evs.gs.washington.edu/EVS/
9. The 1000 Genomes Browser. Hinxton, Cambridgeshire (UK): The European Bioinformatics Institute (EBI). (1000 Genomes release 13). [cited 2013 Apr 25]; Available from: http://browser.1000genomes.org/index.html.
10. Gross E, Busse B, Riemenschneider M, Neubauer S, Seck K, Klein HG, et al. Strong association of a common dihydropyrimidine dehydrogenase gene polymorphism with fluoropyrimidine-related toxicity in cancer patients. PLoS one 2008;3:e4003
11. Amstutz U, Farese S, Aebi S, Largiader CR. Dihydropyrimidine dehydrogenase gene variation and severe 5-fluorouracil toxicity: a haplotype assessment. Pharmacogenomics 2009;10:931-44
12. Kleibl Z, Fidlerova J, Kleiblova P, Kormunda S, Bilek M, Bouskova K, et al. Influence of dihydropyrimidine dehydrogenase gene (DPYD) coding sequence variants on the development of fluoropyrimidinerelated toxicity in patients with high-grade toxicity and patients with excellent tolerance of fluoropyrimidine-based chemotherapy. Neoplasma 2009;56:303-16
13. Offer SM, Wegner NJ, Fossum C, Wang K, Diasio RB. Phenotypic profiling of DPYD variations relevant to 5-fluorouracil sensitivity using real-time cellular analysis and in vitro measurement of enzyme activity. Cancer Res 2013;73:1958-68
14. Database of Single Nucleotide Polymorphisms (dbSNP). Bethesda (MD): National Center for Biotechnology Information, National Library of Medicine. (dbSNP Build ID: 138). [cited 2013 Apr 25]; Available from: http://www.ncbi.nlm. nih.gov/projects/SNP/snp-ref.cgi?showRare=on&chooseRs=coding&go= Go&locusId=1806.
15. Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P, et al. A method and server for predicting damaging missense mutations. Nat Methods 2010;7:248-9
16. Adzhubei I, Jordan DM, Sunyaev SR. Predicting functional effect of human missense mutations using PolyPhen-2. Curr ProtocHumGenet 2013;Chapter 7:Unit7 20
17. Choi Y, Sims GE, Murphy S, Miller JR, Chan AP. Predicting the functional effect of amino acid substitutions and indels. PLoS One 2012;7:e46688
18. Kumar P, Henikoff S, Ng PC. Predicting the effects of coding nonsynonymous variants on protein function using the SIFT algorithm. Nat protoc 2009;4:1073-81
19. Bromberg Y, Rost B. SNAP: predict effect of non-synonymous polymorphisms on function. Nucleic Acids Res 2007;35:3823-35
20. Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC, et al. UCSF Chimera-a visualization system for exploratory research and analysis. J Comput Chem 2004;25: 1605-12
21. Sali A, Blundell TL. Comparative protein modelling by satisfaction of spatial restraints. J Mol Biol 1993;234:779-815
22. Catalogue of Somatic Mutations in Cancer (COSMIC). Hinxton, Cambridgeshire (UK): Cancer Genome Project, Wellcome Trust Sanger Institute. (COSMIC v64 release). [cited 2013 Apr 25]; Available from: http://cancer.sanger. ac.uk/cancergenome/projects/cosmic/.
23. Bamford S, Dawson E, Forbes S, Clements J, Pettett R, Dogan A, et al. The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website. Br J Cancer 2004;91:355-8
24. Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature 2011;474:609-15
25. Dobritzsch D, Ricagno S, Schneider G, Schnackerz KD, Lindqvist Y. Crystal structure of the productive ternary complex of dihydropyrimidine dehydrogenase with NADPH and 5-iodouracil. Implications for mechanism of inhibition and electron transfer. J Biol Chem 2002;277: 13155-66
26. Dobritzsch D, Schneider G, Schnackerz KD, Lindqvist Y. Crystal structure of dihydropyrimidine dehydrogenase, a major determinant of the pharmacokinetics of the anti-cancer drug 5-fluorouracil.EMBOJ 2001;20:650-60
27. van Kuilenburg AB, Haasjes J, Richel DJ, Zoetekouw L, Van Lenthe H, De Abreu RA, et al. Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracilassociated toxicity: identification of new mutations in the DPD gene. Clin Cancer Res 2000;6:4705-12
28. Deenen MJ, Tol J, Burylo AM, Doodeman VD, de Boer A, Vincent A, et al. Relationship between single nucleotide polymorphisms and haplotypes in DPYD and toxicity and efficacy of capecitabine in advanced colorectal cancer. Clin Cancer Res 2011;17:3455-68
29. van Kuilenburg AB, Haasjes J, Meinsma R, Waterham HR, Vreken P, van Gennip AH. Dihydropyrimidine dehydrogenase (DPD) deficiency: novel mutations in the DPD gene. Adv Exp Med Biol 2000;486:247-50
30. van Kuilenburg AB, Dobritzsch D, Meinsma R, Haasjes J, Waterham HR, Nowaczyk MJ, et al. Novel disease-causing mutations in the dihydropyrimidine dehydrogenase gene interpreted by analysis of the three-dimensional protein structure. Biochem J 2002;364:157-63
31. Kouwaki M, Hamajima N, Sumi S, Nonaka M, Sasaki M, Dobashi K, et al. Identification of novel mutations in the dihydropyrimidine dehydrogenase gene in a Japanese patient with 5-fluorouracil toxicity. Clin Cancer Res 1998;4:2999-3004
32. Cho HJ, Park YS, Kang WK, Kim JW, Lee SY. Thymidylate synthase (TYMS) and dihydropyrimidine dehydrogenase (DPYD) polymorphisms in the Korean population for prediction of 5-fluorouracil-associated toxicity. Ther Drug Monit 2007;29:190-6
33. van Kuilenburg AB, Baars JW, Meinsma R, van Gennip AH. Lethal 5- fluorouracil toxicity associated with a novel mutation in the dihydropyrimidine dehydrogenase gene. Ann Oncol 2003;14:341-2
34. Vreken P, Van Kuilenburg AB, Meinsma R, van Gennip AH. Dihydropyrimidine dehydrogenase (DPD) deficiency: identification and expression of missense mutations C29R, R886H and R235W. Hum Genet 1997;101:333-8
35. Vreken P, van Kuilenburg AB, Meinsma R, van Gennip AH. Dihydropyrimidine dehydrogenase deficiency. Identification of two novel mutations and expression of missense mutations in E. coli. Adv Exp Med Biol 1998;431:341-6
36. Offer SM, Diasio RB. Response to "A Case of 5-FU-Related Severe Toxicity Associated With the P.Y186C DPYD Variant." Clin Pharmacol Ther 2014;95:137
37. Zhou W, Freed CR. Tyrosine-to-cysteine modification of human alphasynuclein enhances protein aggregation and cellular toxicity. J Biol Chem 2004;279:10128-35
38. Caudle KE, Thorn CF, Klein TE, Swen JJ, McLeod HL, Diasio RB, et al. Clinical pharmacogenetics implementation consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing. Clin Pharmacol Ther 2013;94:640-5.